Table 3.

Cross tabulation of disorders, size of sample, source of support, pharmaceutical agents and outcome of papers with Jadad Index above 2

Jadad Index > 2 (N = 10)
	N of papers	Year	Jadad Index	P N W	N of patients	Financial support	Drug dose (mg/day)
Risperidone (N = 7)
Substance abuse	1	2000	3	0 1 0	125	I	2–8
OCD	1	2000	5	1 0 0	36	I	2.2
Pervasive Developmental disorder	3	1998, 2001, 2001	5, 3, 3	3 0 0	31, 38, 13	I, P, P	2.9, 2.9, 1.2
Stuttering	1	1999	3	1 0 0	21	I	<2
Tourette's syndrome	1	2001	5	1 0 0	50	P	3.8
Olanzapine (N = 3)
Depression	1	2001	3	1 0 0	28	P	12.5–13.5
Personality disorder	1	2001	5	1 0 0	28	P	5.33
Post Traumatic Stress disorder	1	2001	3	0 1 0	15	P	14.1
Quetiepine (N = 0)	0	-	-	-	-	-	-

P = improvement of the patients, N = no change, W = worsening of the patients I: supported by State or independent grants P: supported by a pharmaceutical company